论文部分内容阅读
目的探讨重组人脑钠肽对心肌梗死所致急性心力衰竭的疗效和肾功能的影响。方法 92例心肌梗死所致急性心力衰竭患者,按就诊编号分为对照组和研究组,各46例。对照组接受常规治疗,研究组在对照组基础上接受重组人脑钠肽治疗。对比两组治疗效果。结果治疗48 h后,研究组的尿素氮、血肌酐、24 h尿量均高于对照组,血钾水平低于对照组(P<0.05);研究组中心静脉压、心率、毛细血管楔压、肺动脉收缩压均明显低于对照组(P<0.05);研究组呼吸困难总改善率为95.65%,明显高于对照组的80.43%(P<0.05)。结论对心肌梗死所致急性心力衰竭的患者应用重组人脑钠肽治疗,可显著减轻患者症状,提高疗效,改善肾功能。
Objective To investigate the effect of recombinant human brain natriuretic peptide on the efficacy and renal function of acute heart failure induced by myocardial infarction. Methods A total of 92 patients with acute heart failure due to myocardial infarction were divided into the control group and the study group according to the treatment number, each with 46 cases. The control group received routine treatment, and the study group received recombinant human brain natriuretic peptide based on the control group. Compare the two groups treatment effect. Results After 48 h of treatment, the urine urea nitrogen, serum creatinine and 24 h urinary excretion of the study group were higher than those of the control group, and the serum potassium level was lower than that of the control group (P <0.05). The central venous pressure, heart rate, wedge pressure , Pulmonary systolic pressure were significantly lower than the control group (P <0.05). The total improvement rate of dyspnea in study group was 95.65%, which was significantly higher than that of the control group (80.43%, P <0.05). Conclusion The application of recombinant human brain natriuretic peptide in patients with acute heart failure due to myocardial infarction can significantly reduce the symptoms, improve the curative effect and improve renal function.